Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX316 in Advanced/Metastatic Solid Tumors
NCT07541534Phase 1Recruiting
- Sponsor
- Henlius
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of E-688 in solid tumor, ovarian cancer, primary peritoneal cancer (PPC) and 1 more (2 arms), sponsored by Henlius. Primary endpoints: Dose-Limiting Toxicity at 21 days, Maximum Tolerated Dose at 18 months and 2 more. Started May 2026; status: recruiting.
02
Drugs
E-688
03
Conditions
solid tumorovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT07541534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07541534.